8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                             Current Report Pursuant
                          to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) March 30, 2006


                           PRESSURE BIOSCIENCES, INC.
- --------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)


                                  MASSACHUSETTS
- --------------------------------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)


           0-21615                                      04-2652826
- -------------------------------             -----------------------------------
   (Commission File Number)                 (I.R.S. Employer Identification No.)


321 Manley Street, West Bridgewater, MA                    02379
- ----------------------------------------    -----------------------------------
(Address of Principal Executive Offices)                (Zip Code)


                                 (508) 580-1818
- --------------------------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)


                                       N/A
- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


Item 1.01   Entry into a Material Definitive Agreement.
            ------------------------------------------

The Company Orders 25 Bench Top Barocycler Units.
- -------------------------------------------------

On April 3, 2006, the Company placed an order for 25 Barocycler NEP 3229 units
from Source Scientific, LLC, the manufacturer of the Company's PCT equipment and
disposable products line. The purchase price for the 25 Barocycler NEP 3229
units is based upon a cost plus arrangement. The units will be manufactured and
shipped in accordance with an agreed upon timeline.

The disclosure contained under this section in this Item 1.01 represents a
summary description of the purchase order with Source Scientific LLC and is
qualified in its entirety by reference to the full text of the purchase order,
which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is
hereby incorporated herein by reference in its entirety.

Richard T. Schumacher.
- ---------------------

On March 30, 2006, the Board of Directors of Pressure BioSciences, Inc.
authorized an increase in the annual salary for Richard T. Schumacher, President
and Chief Executive Officer of the Company, from $250,000 per year to $275,000
per year. The Board of Directors also approved a bonus of $150,000 for Mr.
Schumacher for his services during 2005 and granted him options to purchase
30,000 shares of the Company's Common Stock at an exercise price of $3.86 per
share. The options were issued pursuant to the Company's 2005 Equity Incentive
Plan, and are subject to a three year vesting schedule commencing one year from
the date of grant. The options expire ten years after grant.

Edward H. Myles.
- ---------------

See Item 5.02 below.

Item 5.02   Departure of Directors or Principal Officers; Election of Directors;
            -------------------------------------------------------------------
            Appointment of Principal Officers.
            ---------------------------------

(c)      Appointment of Principal Financial Officer

         Effective April 3, 2006, Edward H. Myles was elected to serve as Vice
President of Finance and Chief Financial Officer of the Company.

         Mr. Myles will be paid a annual salary of $170,000 and will be eligible
for a bonus of up to 10% of his salary based upon the achievement of specific
accomplishments to be determined by the Board of Directors. Mr. Myles was also
granted incentive stock options to purchase 55,000 shares of the Company's
common stock at an exercise price of $3.86. The options were issued pursuant to
the Company's 2005 Equity Incentive Plan and are subject to a three year vesting
schedule commencing one year from the date of grant. The options expire ten
years after grant. Further, the Company will reimburse Mr. Myles for actual
costs incurred to relocate from North Carolina to Massachusetts. If Mr. Myles is
terminated without cause, he will be entitled to receive severance in an amount
equal to one year base salary.

                                       2


         Mr. Myles has more than 12 years of finance and accounting experience,
most recently as Controller for EMD Pharmaceuticals, a wholly-owned affiliate of
Merck KGaA. Prior to EMD, Mr. Myles held various financial positions at SG Cowen
Securities Corporation, Boston Biomedica, and PricewaterhouseCoopers. Mr. Myles
became a CPA in 1996, and earned a B.S.B.A. in accounting and finance from the
University of Hartford and an MBA from Washington University in St. Louis.

Item 9.01   Financial Statements and Exhibits.
            ---------------------------------

(d)      Exhibits

- --------------------------------------------------------------------------------
Exhibit
 Number            Exhibit Description
- --------------------------------------------------------------------------------

   10.1            Purchase Order with Source Scientific LLC dated April 3, 2006

   99.1            Press Release dated April 3, 2006

   99.2            Press Release dated April 5, 2006


                                       3


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: April 5, 2006                   PRESSURE BIOSCIENCES, INC.


                                       By: /s/ RICHARD T. SCHUMACHER
                                           -------------------------------------
                                           Richard T. Schumacher,
                                           President and Chief Executive Officer


                                       4


                                  EXHIBIT INDEX

- --------------------------------------------------------------------------------
Exhibit
 Number            Exhibit Description
- --------------------------------------------------------------------------------

   10.1            Purchase Order with Source Scientific LLC dated April 3, 2006

   99.1            Press Release dated April 3, 2006

   99.2            Press Release dated April 5, 2006



                                       5

EX-10.1

EXHIBIT 10.1

6

7

EX-99.1

                                                                    EXHIBIT 99.1

FOR IMMEDIATE RELEASE

Investor Contacts:
Richard T. Schumacher, President & CEO                Pressure BioSciences, Inc.
R. Wayne Fritzsche, Chairman                                  (508) 580-1818 (T)

              PRESSURE BIOSCIENCES, INC. PROVIDES CORPORATE UPDATE


West Bridgewater, MA, April 3, 2006 - Pressure BioSciences, Inc. (NASDAQ: PBIO)
today provided an update on corporate activities of the past several months,
including the announcement of two additions and one promotion to its senior
management staff.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "We are pleased
to announce that Mr. Edward H. Myles has been hired as our new Vice President of
Finance and Chief Financial Officer; Dr. Nathan P. Lawrence has been promoted to
the newly created position of Vice President of Marketing and Business
Development; and Dr. Alexander V. Lazarev has been hired as Director of Research
and Development, a position that became vacant following the promotion of Dr.
Lawrence."

Mr. Schumacher continued: "In addition to these important senior management
changes, several additional events have occurred over the past several months
that have served to strengthen our balance sheet and help solidify the overall
health of our company, specifically: (1) we have received the remaining escrow
funds from the SeraCare transaction (approximately $1.1 million); (2) we have
received approximately $518,000 from the sale of 57,900 shares of Panacos
Pharmaceuticals; (3) we have secured state-of-the-art laboratory space for our
R&D activities in Woburn Massachusetts; (4) we have begun working with
collaborators who are recognized experts in the areas of forensics,
anti-bioterrorism, and agriculture; and (5) we have reported financial results
in our Form-10KSB that were in line with internal expectations. As a company, we
look forward to the future with excitement and anticipation."

About Mr. Edward H. Myles

Mr. Myles has more than 12 years of finance and accounting experience, most
recently as Controller for EMD Pharmaceuticals, a wholly-owned affiliate of
Merck KGaA. Prior to EMD, Mr. Myles held various financial positions at SG Cowen
Securities Corporation, Boston Biomedica, and PricewaterhouseCoopers. Mr. Myles
became a CPA in 1996, and earned a B.S.B.A. in accounting and finance from the
University of Hartford and an MBA from Washington University in St. Louis.

About Dr. Nathan P. Lawrence

Dr. Lawrence was Director of Research and Development at Pressure BioSciences
prior to his promotion to Vice President of Marketing and Business Development.
Prior to PBI, Dr. Lawrence held various scientific positions at 454 Life
Sciences, Boston Biomedica, Becton Dickinson, and Gene-Trak Systems. Dr.
Lawrence earned his B.A. at the University of Miami, his M.S. at Southern
Connecticut State University, and his Ph.D. at Yale University.

                                       8


About Dr. Alexander V. Lazarev

Dr. Lazarev was most recently Director of New Technology Development at Proteome
Systems, Inc. (PSI). Prior to PSI, Dr. Lazarev held various scientific positions
at Genomic Solutions, Inc., PhytoChem Technologies, Inc., Ohio State University
School of Medicine, and the Uniformed Services University of Health Sciences.
Dr. Lazarev earned his undergraduate and graduate degrees at the University of
Kazan, Russian Federation.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company
focused on the development of a novel technology called Pressure Cycling
Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and
ultra-high levels (up to 35,000 psi and greater) to control bio-molecular
interactions. PBI currently holds 13 US and 4 foreign patents covering multiple
applications of PCT in the life sciences field, including in such areas as
genomic and proteomic sample preparation, pathogen inactivation, the control of
enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions,
hopes, beliefs, expectations or predictions of the future are "forward-looking''
statements within the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the Company's expectations about the
future. These statements are based upon the Company's current expectations,
forecasts, and assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ materially from
those indicated by these forward-looking statements. These risks, uncertainties,
and other factors include, but are not limited to: fluctuations in the Company's
financial and operating results, which could adversely affect the Company's cash
flow; uncertainties inherent in the development of new products, including the
Company's new Bench Top PCT instrument, including technical risks, cost
overruns, and manufacturing and other delays; the risk that newly introduced
products may contain undetected errors or defects or otherwise not perform as
anticipated; the risk that the Company's products will not achieve market
acceptance; the risk that the Company will not be able to increase demand or
sales for its products; the risk that the Company will face adverse changes in
the Company's liquidity and capital resources; the risk that the Company will be
unable to attract and retain qualified personnel; the risk that the hiring of
Mr. Myles and Dr. Lazarev and the promotion of Dr. Lawrence may not benefit the
Company; declines in the market price of the Company's common stock; declines in
the market price of Panacos Pharmaceuticals common stock; the risk that the
Company's shares of Panacos Pharmaceuticals common stock held in escrow may not
be released to the Company in September 2006; the risk that loans from the
Company may not be repaid; changes in the capital markets; competition; general
and industry-specific economic conditions; and the other risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual Report on
Form 10-KSB for the year ended December 31, 2005 and other reports filed by the
Company from time to time with the SEC. The Company undertakes no obligation to
update any of the information included in this release, except as otherwise
required by law.


           Visit us at our website http://www.pressurebiosciences.com

                                       9

EX-99.2

                                                                    EXHIBIT 99.2

FOR IMMEDIATE RELEASE

Investor Contacts:
Richard T. Schumacher, President & CEO                Pressure BioSciences, Inc.
Edward H. Myles, VP of Finance and CFO                        (508) 580-1818 (T)


                   PRESSURE BIOSCIENCES, INC. PLACES ORDER FOR
            25 BENCH TOP BAROCYCLER UNITS FROM SOURCE SCIENTIFIC, LLC

West Bridgewater, MA, April 5, 2006 - Pressure BioSciences, Inc. (NASDAQ: PBIO)
today announced it has placed an order for 25 Barocycler NEP3229 units with
Source Scientific, LLC, the manufacturer of the Company's PCT equipment and
disposable products line. The NEP3229 is the new bench top version of the
Company's pressure cycling instrument (the Barocyler), designed to be a more
cost-effective and user-friendly alternative to the original floor model
Barocycler instrument, the NEP2017. Sixteen NEP3229 units were initially
manufactured between June and December of 2005 as part of the Company's
strategic plan to have the instruments evaluated in leading laboratories
throughout North America and Japan. Of these sixteen units, five have been sold,
six are in the laboratories of collaborators, three will soon be shipped to new
collaborator sites, and two are being used for internal R&D.

Richard T. Schumacher, Founder, President, and CEO of PBI said: "The safe,
efficient, and reproducible extraction of DNA, RNA, proteins, and small
molecules from cell and tissue samples is essential to the tens of thousands of
investigators working in genomic and proteomic research today. This is true
regardless whether the researcher is working with human, animal, plant, or
microbial materials. To that end, we believe that the PCT Sample Preparation
System (PCT SPS) offers many clear and important advantages over all other
extraction methods currently available, especially for those samples generally
considered "hard-to-lyse" (i.e., hard to open). Over the past year, we have been
working diligently with collaborators to help generate the data necessary to
highlight these advantages. We are therefore very pleased that investigators
from several nationally-recognized laboratories have recently given
presentations at scientific meetings that underscore the advantages of the PCT
SPS."

Mr. Schumacher continued: "Because of this increased interest in the PCT SPS, we
placed an order with Source Scientific for 25 Barocycler NEP3229 units to be
delivered over the course of 2006. These new, bench top instruments will give us
the opportunity to work with thought leaders and experts in new and important
areas of the life sciences, as well as to have a significant number of
instruments readily available for sale."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company
focused on the development of a novel technology called Pressure Cycling
Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and
ultra-high levels (up to 35,000 psi and greater) to control bio-molecular

                                       10


interactions. PBI currently holds 13 US and 4 foreign patents covering multiple
applications of PCT in the life sciences field, including in such areas as
genomic and proteomic sample preparation, pathogen inactivation, the control of
enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions,
hopes, beliefs, expectations or predictions of the future are "forward-looking''
statements within the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the magnitude of the need by
investigators to extract DNA, RNA, proteins, and small molecules from cell and
tissue samples, the Company's expectations about the market interest in the PCT
SPS, the purchase of the 25 additional NEP3229 units, the Company's expectations
about the addition of new collaboration sites, and the potential for the sale of
some or all of the additional 25 instruments. These statements are based upon
the Company's current expectations, forecasts, and assumptions that are subject
to risks, uncertainties, and other factors that could cause actual outcomes and
results to differ materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include, but are not
limited to: fluctuations in the Company's financial and operating results that
could adversely affect the Company's cash flow; uncertainties inherent in the
development of the PCT SPS, including technical risks, cost overruns, and
manufacturing and other delays; the risk that the market will not recognize the
advantages of the PCT SPS over other currently available extraction methods; the
risk that the Company will not be able to increase demand or sales for its
products; and the other risks and uncertainties discussed under the heading
"Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended
December 31, 2005 and other reports filed by the Company from time to time with
the SEC. The Company undertakes no obligation to update any of the information
included in this release, except as otherwise required by law.


           Visit us at our website http://www.pressurebiosciences.com

                                       11